Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study

Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study

Octreotide long-acting repeatable (LAR) is largely used to treat functional and/or metastatic neuroendocrine neoplasms (NENs). Its effect in controlling carcinoid syndrome and partially reduce tumour burden is attributable to the ability of octreotide to bind somatostatin receptors (SSTRs) on the tu...

Full description

Bibliographic Details
Main Authors: Claudia von Arx, Giuseppina Rea, Maria Napolitano, Alessandro Ottaiano, Fabiana Tatangelo, Francesco Izzo, Antonella Petrillo, Ottavia Clemente, Antonella Di Sarno, Gerardo Botti, Stefania Scala, Salvatore Tafuto
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
neuroendocrine tumors
octreotide
Tregs
MDSCs
immune-response modulation
Online Access:https://www.mdpi.com/2072-6694/12/9/2422

Internet

https://www.mdpi.com/2072-6694/12/9/2422

Similar Items